Sartorius Stedim Biotech S.A.

ENXTPA:DIM Stock Report

Market Cap: €17.2b

Sartorius Stedim Biotech Future Growth

Future criteria checks 4/6

Sartorius Stedim Biotech is forecast to grow earnings and revenue by 20.9% and 9.7% per annum respectively. EPS is expected to grow by 21.8% per annum. Return on equity is forecast to be 13% in 3 years.

Key information

20.9%

Earnings growth rate

21.80%

EPS growth rate

Life Sciences earnings growth20.0%
Revenue growth rate9.7%
Future return on equity13.03%
Analyst coverage

Good

Last updated23 Jun 2026

Recent future growth updates

Analysis Article • Apr 26

Earnings Miss: Sartorius Stedim Biotech S.A. Missed EPS By 7.2% And Analysts Are Revising Their Forecasts

It's been a sad week for Sartorius Stedim Biotech S.A. ( EPA:DIM ), who've watched their investment drop 14% to €162 in...

Recent updates

Analysis Article • Apr 26

Earnings Miss: Sartorius Stedim Biotech S.A. Missed EPS By 7.2% And Analysts Are Revising Their Forecasts

It's been a sad week for Sartorius Stedim Biotech S.A. ( EPA:DIM ), who've watched their investment drop 14% to €162 in...
Analysis Article • Feb 14

A Look At The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)

Key Insights Sartorius Stedim Biotech's estimated fair value is €191 based on 2 Stage Free Cash Flow to Equity With...
Narrative Update • Feb 09

DIM: Bioprocessing Recovery Expectations Will Drive Constructive Outlook Despite Recent Downgrades

Narrative Update: Sartorius Stedim Biotech The analyst fair value estimate for Sartorius Stedim Biotech has edged from about €241 to €240 as analysts factor in recent downgrades that point to the bioprocessing recovery and recent share outperformance already being reflected in the current price. Analyst Commentary Recent research updates around Sartorius Stedim Biotech are clustered around the view that the current share price already captures a meaningful part of the expected recovery in bioprocessing.
Analysis Article • Jan 30

What Is Sartorius Stedim Biotech S.A.'s (EPA:DIM) Share Price Doing?

Sartorius Stedim Biotech S.A. ( EPA:DIM ) saw significant share price movement during recent months on the ENXTPA...
Narrative Update • Jan 24

DIM: Bioprocessing Recovery Expectations Will Shape Constructive Outlook Despite Rating Downgrades

Analysts have trimmed their fair value estimate for Sartorius Stedim Biotech by a fraction to about €241, reflecting a mix of more cautious ratings after recent share outperformance and recovery expectations in bioprocessing that are now seen as better reflected in the price, even as some targets, such as the €250 level, have edged higher. Analyst Commentary Recent research paints a mixed picture for Sartorius Stedim Biotech, with price targets clustering in the €240 to €250 range and ratings moving toward more neutral stances after the share price recovery.
Analysis Article • Jan 14

Why We're Not Concerned About Sartorius Stedim Biotech S.A.'s (EPA:DIM) Share Price

Sartorius Stedim Biotech S.A.'s ( EPA:DIM ) price-to-earnings (or "P/E") ratio of 79.2x might make it look like a...
Narrative Update • Jan 06

DIM: Raised 2025 Guidance And Updated Assumptions Will Shape Balanced Outlook

Analysts have nudged their price expectations for Sartorius Stedim Biotech higher, with one recent move lifting a target to €250 from €230. This change reflects updated assumptions around discount rates, growth and P/E inputs.
Narrative Update • Dec 22

DIM: Raised 2025 Guidance Will Support Stronger Prospects Ahead

Analysts have modestly raised their price target for Sartorius Stedim Biotech to approximately €241 from about €237, citing a slightly higher assumed future valuation multiple that more than offsets marginally lower growth and profitability expectations. What's in the News Sartorius Stedim Biotech raised its 2025 sales revenue growth guidance to around 9 percent, up from a prior forecast of 7 percent plus or minus 2 percentage points.
Analysis Article • Dec 15

Here's Why Sartorius Stedim Biotech (EPA:DIM) Can Manage Its Debt Responsibly

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Narrative Update • Dec 08

DIM: Higher Future Multiple Will Support Stronger Prospects Ahead

Analysts have raised their price target for Sartorius Stedim Biotech by approximately €5 to around €237, citing slightly improved profit margin expectations and a willingness to apply a higher future price-to-earnings multiple, despite modestly softer revenue growth forecasts. What's in the News Sartorius Stedim Biotech raised its 2025 sales revenue growth guidance to around 9 percent, up from the prior forecast of 7 percent with a plus/minus 2 percentage point range (company guidance).
Narrative Update • Oct 17

High Consumable Demand And Regulatory Standards Will Drive Future Success

Analysts have modestly raised their price target for Sartorius Stedim Biotech from €229.62 to €231.92. They cited improved revenue growth and higher profit margin projections as key drivers for the adjustment.
Analysis Article • Oct 17

Is Sartorius Stedim Biotech S.A. (EPA:DIM) Potentially Undervalued?

Sartorius Stedim Biotech S.A. ( EPA:DIM ) led the ENXTPA gainers with a relatively large price hike in the past couple...
Narrative Update • Oct 03

High Consumable Demand And Regulatory Standards Will Drive Future Success

Analysts have slightly lowered their price target for Sartorius Stedim Biotech from €233.31 to €229.62, citing minor adjustments in discount rates and projected revenue growth. What's in the News Sartorius Stedim Biotech and Bio Usawa Biotechnology announced a strategic partnership to accelerate Africa's biopharmaceutical industry.
Analysis Article • Aug 29

Is There An Opportunity With Sartorius Stedim Biotech S.A.'s (EPA:DIM) 21% Undervaluation?

Key Insights The projected fair value for Sartorius Stedim Biotech is €221 based on 2 Stage Free Cash Flow to Equity...
Analysis Article • Jul 17

Is There Now An Opportunity In Sartorius Stedim Biotech S.A. (EPA:DIM)?

Sartorius Stedim Biotech S.A. ( EPA:DIM ) saw a significant share price rise of 27% in the past couple of months on the...
Analysis Article • Jul 01

Is Sartorius Stedim Biotech (EPA:DIM) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
User avatar
New Narrative • Nov 07

Increased Order Intake And Efficiency Drive Future Growth Amidst Global Challenges

Increased order intake for consumables indicates future recurring revenue stability as customer destocking improves, highlighting positive growth trends.

Earnings and Revenue Growth Forecasts

ENXTPA:DIM - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20283,8865676151,04113
12/31/20273,50247547893113
12/31/20263,17138038081713
3/31/20262,984268368766N/A
12/31/20252,968266299692N/A
9/30/20252,947264375731N/A
6/30/20252,896225497788N/A
3/31/20252,858204584880N/A
12/31/20242,780175475815N/A
9/30/20242,736161504866N/A
6/30/20242,747170305706N/A
3/31/20242,716255169636N/A
12/31/20232,776310273746N/A
9/30/20232,959460113625N/A
6/30/20233,170635162675N/A
3/31/20233,356717137606N/A
12/31/20223,493876182612N/A
9/30/20223,381681125552N/A
6/30/20223,259625193584N/A
3/31/20223,094559322661N/A
12/31/20212,887414378702N/A
9/30/20212,639523355623N/A
6/30/20212,393469367590N/A
3/31/20212,143398310506N/A
12/31/20201,910336258417N/A
9/30/20201,743299299414N/A
6/30/20201,600255243365N/A
3/31/20201,520254216345N/A
12/31/20191,441235N/A310N/A
9/30/20191,393247N/A291N/A
6/30/20191,336238N/A261N/A
3/31/20191,274223N/A270N/A
12/31/20181,212208N/A227N/A
9/30/20181,172185N/A226N/A
6/30/20181,121173N/A225N/A
3/31/20181,093162N/A196N/A
12/31/20171,081161N/A175N/A
9/30/20171,073151N/A165N/A
6/30/20171,089157N/A169N/A
3/31/20171,075157N/A146N/A
12/31/20161,052154N/A157N/A
9/30/20161,009145N/A146N/A
6/30/2016971142N/A129N/A
3/31/2016926136N/A155N/A
12/31/2015884118N/A143N/A
9/30/2015850111N/A150N/A
6/30/201578189N/A128N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DIM's forecast earnings growth (20.9% per year) is above the savings rate (2.5%).

Earnings vs Market: DIM's earnings (20.9% per year) are forecast to grow faster than the French market (12.3% per year).

High Growth Earnings: DIM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: DIM's revenue (9.7% per year) is forecast to grow faster than the French market (5.7% per year).

High Growth Revenue: DIM's revenue (9.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: DIM's Return on Equity is forecast to be low in 3 years time (13%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/26 17:35
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sartorius Stedim Biotech S.A. is covered by 25 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charles PitmanBarclays
Nithya BalasubramanianBernstein
Delphine Le LouetBernstein